1. Scrip
  2. >>Therapy Areas

Pfizer Eyes First-To-Market Opportunity In Alopecia

 
• By Jessica Merrill

Inflammation and Immunology Chief Scientific Officer Michael Vincent talked to Scrip about the first positive Phase II data testing a JAK inhibitor for hair loss caused by alopecia areata, next steps for development and the broader I&I portfolio.

Front view of a balding woman before and after hair treatment. Divided image of the head. Two halves. Sticker revealing healthy scalp. Female alopecia. Isolated vector illustration.

Pfizer Inc. has an opportunity to be first-to-market with a drug for alopecia areata (AA), an autoimmune disease characterized by hair loss and often associated with psychological consequences. The company is advancing an oral Janus kinase (JAK) 3 inhibitor into a Phase IIb/III trial within months, now that the drug has shown a statistically significant efficacy benefit in a Phase IIa study.

The Phase IIa data mark a drug development breakthrough for treating AA, a disease in which immune cells attack healthy hair follicles for which there are no approved drugs

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.